Consolidated Statements of Equity - USD ($) $ in Thousands	Total	OPKO Health Europe	Common Stock	Treasury	Treasury OPKO Health Europe	Additional Paid-In Capital	Additional Paid-In Capital OPKO Health Europe	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance, shares (in shares) at Dec. 31, 2016			558,576,051	(586,760)
Beginning balance at Dec. 31, 2016	$ 2,046,433		$ 5,586	$ (1,911)		$ 2,845,096		$ (27,009)	$ (775,329)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	28,307					28,307
Exercise of Common Stock options and warrants (in shares)			1,447,694
Exercise of Common Stock options and warrants	2,132		$ 14			2,118
Reclassification of embedded derivatives to equity	13,551					13,551
Issuance of Treasury Stock in connection with OPKO Health Europe's Contingent Consideration (in shares)					36,853
Issuance of Treasury Stock in connection with OPKO Health Europe's Contingent Consideration		$ 304			$ 120		$ 184
Net loss	(305,250)								(305,250)
Other comprehensive loss	26,481							26,481
Ending balance, shares (in shares) at Dec. 31, 2017			560,023,745	(549,907)
Ending balance at Dec. 31, 2017	1,843,623		$ 5,600	$ (1,791)		2,889,256		(528)	(1,048,914)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	21,761					21,761
Exercise of Common Stock options and warrants (in shares)			353,677
Exercise of Common Stock options and warrants	1,174		$ 4			1,170
Sale of common stock (in shares)			26,504,298
Sale of common stock	92,500		$ 265			92,235
Net loss	(153,040)								(153,040)
Other comprehensive loss	(14,727)							(14,727)
Ending balance, shares (in shares) at Dec. 31, 2018			586,881,720	(549,907)
Ending balance at Dec. 31, 2018	1,791,291		$ 5,869	$ (1,791)		3,004,422		(20,131)	(1,197,078)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	$ 13,421					13,421
Exercise of Common Stock options and warrants (in shares)	24,877		19,232
Exercise of Common Stock options and warrants	$ (3)					(3)
2025 convertible notes including share lending agreement (in shares)			29,250,000
2025 convertible notes including share lending agreement	50,852		$ 293			50,559
Sale of common stock (in shares)			54,227,749
Sale of common stock	76,062		$ 542			75,520
Net loss	(314,925)								(314,925)
Ending balance, shares (in shares) at Dec. 31, 2019			670,378,701	(549,907)
Ending balance at Dec. 31, 2019	$ 1,614,759		$ 6,704	$ (1,791)		$ 3,142,993		$ (22,070)	$ (1,511,077)